What CombinAble.AI does

CombinAble.AI is an Israel-based biotechnology technology company that developed a physics-informed, AI-driven optimization engine for biologics drug design. The company's core technology combines physics-based modeling with machine learning to optimize biologic drug candidates, treating potency and manufacturability as interdependent design criteria from the outset of drug design rather than through sequential optimization. The stated aim is to reduce late-stage development failures caused by manufacturing issues that typically surface only after potency has already been optimized.

The company focused on large-molecule therapeutics spanning antibodies, oligonucleotides, and complex biologics, serving pharmaceutical and biotechnology drug-discovery organizations through a horizontal B2B go-to-market model. Pricing, contract structure, named customers, and funding-round history were not publicly disclosed, consistent with the company's private status and lean team of 1–10 employees based in Rehovot, Israel. No product revenue or ARR was reported in available sources, and patents, certifications, and management-team details were absent from the input data.

In January 2026, insitro announced the acquisition of CombinAbleAI (expected to close late January 2026), integrating the company's physics-informed AI optimization engine into insitro's existing TherML platform to produce a full-stack, modality-agnostic drug discovery platform covering small molecules, oligonucleotides, antibodies, and complex biologics. The CombinAbleAI team continued to operate in Rehovot as a newly established insitro R&D center focused on large molecule design, extending insitro's operational footprint into Israel alongside its existing presence in the US, Poland, and Malaysia.

Name

CombinAble.AI

Legal name

CombinAble.AI

Website

https://combinableai.com

Company type

Private

Operating status

Acquired

Headcount range

1–10 employees

Short description

CombinAble.AI is an Israel-based biotech startup that built a physics-informed AI optimization engine for biologics drug design, treating potency and manufacturability as joint design criteria. Acquired by insitro in January 2026; the team continues operating in Rehovot as insitro's R&D center for large molecule therapeutics.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI drug discovery
• Biologics design
• Antibody optimization
• Large molecule therapeutics
• Physics-informed AI

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel

Core offering

CombinAble.AI developed a physics-informed, AI-driven optimization engine for biologics drug design. The platform combines physics-based modeling with machine learning to simultaneously optimize drug potency and manufacturability as interdependent design criteria, addressing late-stage development failures in antibody and complex biologic discovery.

Product overview

CombinAble.AI was an independent company offering physics-informed AI-driven optimization for biologics drug discovery. In January 2026, it was acquired by insitro. The CombinAbleAI technology is being integrated into insitro's TherML platform, which unifies therapeutic design across small molecules, oligonucleotides, antibodies, and complex biologics. The CombinAbleAI team now operates as an insitro R&D center in Israel focused on large molecule design.

Differentiator

Problem solved

Functional benefit

Products and services

• CombinAbleAI Physics-Informed AI Platform

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Partnerships

One partnership is on record.

• insitrocoreStrategic or Co-development Partner · 12 January 2026insitro acquired CombinAbleAI to complete its full-stack, modality-agnostic AI platform for drug discovery. The CombinAbleAI team continues operating in Israel as a new insitro R&D center focused on large molecule design. The acquisition enables integration of CombinAbleAI's physics-informed AI-driven optimization engine for biologics with insitro's existing capabilities, forming the combined TherML platform for unified therapeutic design.

Recent moves3 records

Expansion highlights5 records

Broad incumbents

• Isomorphic Labs: AI-first drug discovery company spun out of DeepMind, pursuing AI-driven drug design across small molecules and biologics. Comparable as a broad incumbent in AI-driven therapeutic discovery.
• Insitro: AI-driven drug discovery company that acquired CombinAble.AI; operates a full-stack, modality-agnostic TherML platform. The acquirer and parent of CombinAble.AI's operations post-acquisition, with overlapping capabilities in ML-enabled therapeutic design.

Direct peers

• BigHat Biosciences: AI/ML-driven antibody design platform that integrates wet-lab experimentation with computational optimization. Highly comparable to CombinAble.AI's focus on AI-enabled antibody engineering and manufacturability-aware design.
• Cradle: AI platform for protein engineering that helps biotech companies design and optimize proteins with improved properties. Comparable in targeting protein/antibody optimization using machine learning.
• Profluent: AI-driven protein design company using foundation models to engineer novel proteins and antibodies. Comparable as a competitor in AI-enabled protein and biologic engineering.
• EvolutionaryScale: AI research company developing frontier models for biology, with applications in protein and biologic design. Comparable to CombinAble.AI in applying large-scale AI to biologics engineering.
• Iambic: AI-driven drug discovery company applying machine learning across multiple therapeutic modalities including biologics. Comparable in modality-agnostic AI drug discovery and optimization.
• Generate Biomedicines: Generative AI platform for designing novel protein therapeutics across multiple modalities. Directly comparable in applying AI to biologics design, including antibodies and complex proteins.
• AbCellera Biologics: Public antibody discovery company using AI and high-throughput screening to discover and optimize therapeutic antibodies. Directly comparable to CombinAble.AI as both apply computational approaches to antibody and biologics design for pharma partners.

Emerging players

• Genesis Therapeutics: AI-driven drug discovery company combining graph neural networks and other AI techniques for molecular design. Partially comparable as an emerging player in AI-enabled drug design, though focused more on small molecules than biologics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/combinable-ai

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CombinAble.AI